Home' Australian Pharmacist : Australian Pharmacist November 2015 Contents Australian Pharmacist November 2015 I ©Pharmaceutical Society of Australia Ltd.
New atypical antipsychotic
From 1 November 2015, Australians
suffering from schizophrenia will have
a new treatment choice.
LATUDA (lurasidone), a new atypical
antipsychotic will be PBS listed
for the treatment of adults with
• LATUDA has demonstrated efficacy
in the acute and long-term treatment
• LATUDA is well tolerated with
negligible effect on weight and
metabolic parameters including total
cholesterol, triglycerides & glucose
LATUDA, available in 40 mg and 80 mg
tablet strengths, is taken once daily
Refer to the Product Information
for more details. Servier Drug
Information 1800 153 590 or email
1. Australian Approved Product Information.
2. Meltzer H et al. Am J Psychiatry 2011; 168: 957-967.
3. Stahl S et al. J Clin Psychiatry 2013; 74: 507-15.
4. Loebel A et al. Schizophr Res 2013; 147: 95-102
5. Loebel A et al. Schizophr Res 2013; 145: 101-9
6. Citrome L et al. Int Clin Psychopharmacol 2012; 27:
7. Mattingly G et al. Eur Neuropsychopharmacol. 2014; 24
Servier Laboratories (Australia) Pty. Ltd.
8 Cato Street Hawthorn VIC 3122. Telephone 1800 153 590.
An international research review has
indicated that chondroitin sulfate
may help to reduce pain for arthritis
sufferers. The 2015 Cochrane review
of international research trials found
chondroitin, alone or in combination
with glucosamine, was better than
placebo in improving pain in people
with mild osteoarthritis. Osteoarthritis
affects more than 1.8 million people in
Australia and costs the country more
than $2.03 billion every year.
BioCeuticals Senior Educator Belinda
Reynolds said the extensive Cochrane
review examined 43 studies on
chondroitin involving 9,110 people.
‘It showed that chondroitin reduces
knee pain by 20% and slows down the
narrowing of joint space width on X-rays
of the affected joint. People who took
chondroitin also had pain scores 10%
lower than those who took a placebo.
Those who took chondroitin rated
after 6 months while those who took a
placebo rated their pain at 28 out of 100.’
‘New to the Australian market is a
form of chondroitin called Bioiberica’s
BioActive chondroitin sulfate which
was used as the basis for the USP
monograph on chondroitin, a testament
to its purity and quality profile.
BioCeuticals new Chondroitin BioActive
is a unique combination of Bioiberica’s
CS BioActive chondroitin sulfate and
Boswellia serrata standardised to 30%
acetyl-11 -keto-beta-boswellic acid
(AKBA). With a therapeutic one-a -day
dose, Chondroitin BioActive provides
800 mg of chondroitin.
QV Baby range
The Ego QV Baby range has won three
awards in the 2015 annual Australian
Mother & Baby Magazine Awards with
QV Baby Moisturising Cream taking the
Gold award for the Most Popular Baby
QV Baby Barrier Cream was awarded
silver in the most popular nappy rash
product category and QV Baby Gentle
Wash placed Bronze in the Best Baby
Hair product category. The winning
baby products of the year were all tried,
tested and voted on by real mothers,
babies and the Mother & Baby’s expert
panel. The products submitted were
assessed on quality, value for money,
user-friendliness and innovation.
Scientific and Affairs Manager at Ego
Pharmaceuticals Dr Kerryn Greive PhD,
who oversees the product formulation
of QV, said it was the highest honour
to receive such positive recognition
from Mothers. ‘QV was originally
formulated for the Queen Victoria
Hospital maternity ward in 1965 – 40
years on, it has become an iconic brand
caring Australian families and this award
reinforces the trust that parents have
in QV to care for their precious babies.
Our QV Baby range mimics the way the
skin functions and uses ingredients that
help form a protective moisture barrier
over the skin, it is gentle but effective
skincare and we’re very humbled to be
recognised in this way,’ Dr Greive added.
Links Archive Australian Pharmacist October 2015 Australian Pharmacist December 2015 Navigation Previous Page Next Page